Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
The cytokine family including interleukin-2 and -15 (IL-2 and IL-15) started out in a primitive vertebrate species with three related cytokines IL-2, IL-15, and IL-15-like (IL-15L), all sharing binding capacity for receptor chain IL-15Rα. IL-15L was conserved in fishes, reptiles, and some mammals but lost in humans and mice.
In this interview, Dr. Shalin Naik speaks to AZoLifeSciences about his team's latest research that led to the discovery of a new step in the development of T and B cells that could help us to better understand leukemia.
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program - be utilized for the treatment of tumors.
Adoptive transfer of T-cells can extend survival and, at times, treat patients with advanced solid tumors.
Cancer immunotherapies, which empower patients' immune systems to eliminate tumors, are revolutionizing cancer treatment. Many patients respond well to these treatments, sometimes experiencing long-lasting remissions. But some cancers remain difficult to treat with immunotherapy, and expanding the impact of the approach is a high priority.
A groundbreaking new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumor cells through the use of nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component, according to a study published in Cell in October.
Until recently, it was believed that the innate immune system, the body's first line of defense, lacked the ability to remember pathogens like the adaptive immune system.
Immunotherapies, such as checkpoint inhibitor drugs, have made worlds of difference for the treatment of cancer. Most clinicians and scientists understand these drugs to act on what's known as the adaptive immune system, the T cells and B cells that respond to specific threats to the body.
The function of the body’s immune system is to defeat diseases by detecting foreign invaders and then mounting a response against these pathogens.
To identify new potential therapeutic targets for SARS-CoV-2, a team of scientists at the New York Genome Center, New York University, and the Icahn School of Medicine at Mount Sinai, performed a genome-scale, loss-of-function CRISPR screen to systematically knockout all genes in the human genome.
When it comes to defeating cancer, some immune cells are mightier than others. But even the best-trained eye and today's advanced scientific tools have trouble discerning the most powerful tumor-fighting cells from the rest.
Prostate cancer is the most common type of cancer among American men after skin cancer, but the disease does not affect all races equally.
Despite the remarkable successes of immune-based treatments for cancer, not everyone responds to these approaches and relapses do occur.
Ancient embedded elements in our DNA from generations past can activate a powerful immune response to kill cancer cells like an infection.
CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.
The evolution of the refined human immune system has turned into an effective defense system against several diseases, including cancer.
Like people, cells in the human body protect their personal space. They seem to know how much space they need, and if it gets too tight, most cells prefer to break free.
Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related death worldwide, two major treatment strategies have emerged: tyrosine kinase inhibitors and immune checkpoint inhibitors.
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.
Scientists have discovered that a drug that may make some melanoma tumors perceptible to the immune system, enabling them to be better targeted.